Table 1 Description of the cohort and comparison between patients initially managed in the classical ICU and patients initially managed in the temporary ICU
From: Temporary ICUs during the COVID-19 pandemic first wave: description of the cohort at a French centre
All patients (N = 59) | Classical ICU (N = 22) | Temporary ICU (N = 37) | P | ||
|---|---|---|---|---|---|
Epidemiological data | |||||
Age, years, median [IQR] | 56 [48-63.5] | 53 [47.5-62.8] | 57 [50-65] | 0.58 | |
Male sex, n (%) | 41 (69.5) | 17 (77.3) | 11 (64.9) | 0.48 | |
Time between the first symptoms to hospital admission, days, median [IQR] | 7 [4-10] | 6 [3-9] | 7 [5-10] | 0.09 | |
Time between the hospital and ICU admission, days, median [IQR] | 1 [0-2] | 0 [0-1] | 1 [0-2] | 0.15 | |
Comorbidities | |||||
Body Mass Index (kg/m2), median [IQR] | 27.8 [ 24.6-31 ] | 26 [24.4-29.6] | 28.9 [24.9-31.1] | 0.35 | |
Hypertension, n (%) | 30 (50.8) | 12 (54.6) | 18 (48.7) | 0.34 | |
Diabetes, n (%) | 19 (32.2) | 11 (50) | 8 (21.6) | 0.07 | |
Chronic renal insufficiency, n (%) | 4 (6.8) | 2 (9.1) | 2 (5.4) | 0.16 | |
Immunosuppression, n (%) | 6 (10.2) | 3 (13.6) | 3 (8.1) | 0.64 | |
Active smoking, n (%) | 6 (10.2) | 2 (9.1) | 4 (10.8) | 0.71 | |
Severity on admission | |||||
SOFA score, median [IQR] | 5 [4-7] | 4.5 [3-6.8] | 5 [4-7] | 0.40 | |
SAPS II score, median [IQR] | 41 [30-53.5] | 46.5 [26-54] | 40 [31-53] | 0.84 | |
Computed tomographic data | |||||
Chest CT-scan, n (%) | 42 (71.1) | 15 (68.2) | 27 (73) | 0.77 | |
Chest CT-scan degree of lung involvement | Minimal < 25% | 5 (11.9) | 2 (13.3) | 3 (11.1) | 1 |
Mild 25-50% | 23 (54.8) | 7 (46.7) | 16 (59.3) | ||
Moderate or severe > 50% | 14 (33.3) | 6 (40) | 8 (29.6) | ||
Time between Chest CT-scan and ICU admission, days, median [IQR] | -0.6 [-2;0] | 0 [-2;0] | -1 [-2;0] | 0.40 | |
Ventilator features on admission | |||||
Invasive mechanical ventilation, n (%) | 53 (90) | 17 (77.3) | 36 (97.3) | 0.02 | |
PEEP, cmH2O, median [IQR] | 10 [10-11] | 10 [10-11] | 10 [10-10.8] | 0.81 | |
FiO2, %, median [IQR] | 100 [70-100] | 100 [60-100] | 100 [70-100] | 0.61 | |
PaO2/FiO2, median [IQR] | 130 [79.3-191.5] | 160 [89-205] | 122 [78.5-169] | 0.42 | |
Use of adjunct measures and outcome | |||||
Continuous neuromuscular blockers, n (%) | 48 (81.4) | 15 (68.2) | 33 (89.2) | 0.08 | |
Prone positioning, n (%) | 41 (69.5) | 13 (59.1) | 28 (75.7) | 0.24 | |
ECMO, n (%) | 11 (18.6) | 6 (27.3) | 5 (13.5) | 0.30 | |
Vasopressive therapy, n (%) | 39 (66.1) | 12 (54.5) | 27 (73) | < 0.01 | |
Renal replacement therapy for AKI, n (%) | 11 (18.6) | 4 (18.2) | 7 (18.9) | 1 | |
Tracheotomy, n (%) | 14 (23.7) | 4 (18.2) | 10 (27) | 0.54 | |
Interregional transfer | 12 (20.3) | 2 (9.1) | 10 (27) | 0.06 | |
Ventilator-associated pneumonia, n (%) | 30 (50.8) | 8 (47) | 22 (61.1) | 0.11 | |
Early ventilator-associated pneumonia, n (%) | 4 (6.8) | 1 (5.9) | 3 (8.3) | 1 | |
Time between invasive ventilation and ventilator-associated pneumonia, days, median [IQR] | 7 [5-10] | 8 [5-10] | 7 [5-11.5] | 0.38 | |
Duration of invasive ventilation, days | All patients, median [IQR] | 14 [7.5–17.5] | 9 [3.3-19.8] | 16 [8-25] | 0.07 |
Survivors, median [IQR] | 16 [5.3-27.3] | 11[0-20] | 20 [8-29] | 0.10 | |
ICU length of stay, days | All patients, median [IQR] | 15 [8-28] | 8.5 [3.8-19.8] | 17 [9-28] | 0.05 |
Survivors, median [IQR] | 19.5 [8.5-32] | 12 [2-26] | 26 [11-34] | 0.11 | |
ICU mortality rate, n (%) | 21 (35.6) | 9 (40.9) | 12 (32.4) | 0.58 | |
Day-90 mortality rate, n (%) | 21 (35.6) | 9 (40.9) | 12 (32.4) | 0.58 | |